RxDoctor Payments Data

Fawad Ahmed, MD

Nephrology · Orlando, FLNPI 1134157811

Payments from drug & device makers

$13,693in general payments, 2019–2025

Across 534 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$976
  • Travere Therapeutics, Inc.$975
  • Otsuka America Pharmaceutical, Inc.$751
  • plus $7K from 40 others

What the payments were for

  • Travel & lodging$1,96914%
  • Food & beverage$11,59685%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,693 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$230,605
Medicare patients
427
Services billed
2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol160$125,798
OzempicSemaglutide33$28,993
JardianceEmpagliflozin39$27,399
VeltassaPatiromer Calcium Sorbitex24$23,334
KerendiaFinerenone27$22,616
Calcitriol216$3,700
Sevelamer Carbonate19$3,298
Tacrolimus19$2,166
Nifedipine ErNifedipine109$1,785
Calcium Acetate14$1,503
Metolazone16$832
Lisinopril194$822
Losartan Potassium80$558
Carvedilol60$498
Potassium Chloride32$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,099$125,798160 claims
Novo NordiskOzempic$111$28,99333 claims
Boehringer IngelheimJardiance$190$27,39939 claims
BayerKerendia$594$22,61627 claims
ANI Pharmaceuticals, Inc.Valsartan$314$19932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →